Aavocyte, Inc.

High return potential associated with super low risk!
As a biotech start-up, similar to other bio start-ups, Aavocyte has a very high return potential. What is different from most other start-ups is that Aavocyte enjoys an inherent value of super low risk in favor of its investors, which makes Aavocyte a hard-to-find investment opportunity in biotech start-ups.

Series A major terms
• Extra investor protection by satisfying the following conditions before using the investment raised
o IND clinical trials must be allowed by FDA, and
o Total fund raised must be at least $5M
• Maximum common shares to be issued: up to 1,000,000 shares (1/3 total outstanding shares after funding).
• Unit price: $20/share
• Minimum investment: $500,000
• Minimum closing: $5M

If closed with $5M for A, Round B is needed before pre-IPO funding of Round C. It is target to launch Series C together with IPO in 2021-2022.